Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$23.00 USD
+0.55 (2.43%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $22.99 -0.01 (-0.04%) 7:38 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum D VGM
Company Summary
Menlo Park, CA-based Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone.
Corcept’s only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery. The drug was ...
Company Summary
Menlo Park, CA-based Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone.
Corcept’s only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery. The drug was launched in April 2012. Korlym was the first drug to be approved by the Food and Drug Administration (FDA) for patients with Cushing’s syndrome.
Corcept has discovered a large portfolio of proprietary compounds, including relacorilant, exicorilant and miricorilant, that selectively modulate the effects of cortisol but not progesterone.
Corcept is evaluating its lead candidate, relacorilant, in a late-stage study for the treatment of Cushing's syndrome. Several label expansion studies on relacorilant are also currently underway.
Corcept is advancing its selective cortisol modulator, dazucorilant, as a treatment for patients with Amyotrophic Lateral Sclerosis.
The company is evaluating miricorilant in a phase Ib, dose-finding study in patients with presumed non-alcoholic steatohepatitis (NASH). A phase IIb study on miricorilant was initiated in October 2023.
General Information
Corcept Therapeutics Incorporated
149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
Phone: 650-327-3270
Fax: 650-327-3218
Email: ir@corcept.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.18 |
Current Year EPS Consensus Estimate | 0.92 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 22.46 |
52 Week High | 34.28 |
52 Week Low | 20.84 |
Beta | 0.48 |
20 Day Moving Average | 895,660.81 |
Target Price Consensus | 42.80 |
4 Week | -9.57 |
12 Week | -0.13 |
YTD | -31.34 |
4 Week | -5.82 |
12 Week | -1.78 |
YTD | -34.64 |
Shares Outstanding (millions) | 104.08 |
Market Capitalization (millions) | 2,321.05 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 24.34 |
Trailing 12 Months | 23.47 |
PEG Ratio | NA |
vs. Previous Year | 100.00% |
vs. Previous Quarter | 0.00% |
vs. Previous Year | 31.39% |
vs. Previous Quarter | 9.55% |
Price/Book | 4.54 |
Price/Cash Flow | 23.28 |
Price / Sales | 4.81 |
3/31/24 | NA |
12/31/23 | 21.98 |
9/30/23 | 18.99 |
3/31/24 | NA |
12/31/23 | 17.89 |
9/30/23 | 15.67 |
3/31/24 | NA |
12/31/23 | 4.39 |
9/30/23 | 3.54 |
3/31/24 | NA |
12/31/23 | 4.31 |
9/30/23 | 3.48 |
3/31/24 | NA |
12/31/23 | 21.86 |
9/30/23 | 20.20 |
3/31/24 | NA |
12/31/23 | 21.86 |
9/30/23 | 20.20 |
3/31/24 | NA |
12/31/23 | 25.82 |
9/30/23 | 24.89 |
3/31/24 | NA |
12/31/23 | 4.92 |
9/30/23 | 4.48 |
3/31/24 | NA |
12/31/23 | 0.91 |
9/30/23 | 0.90 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |